Recently, molecular therapeutics targeting receptor tyrosine kinase (RTK) aberrations in lung cancer, including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), and immunotherapies have been developed.1 The gene discussed is ALK; the disease is lung carcinoma.